Most Recent
Intellectual Property 2024-09-20 11:30 pm
Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.
Class Actions 2023-03-03 5:50 pm
A law firm has won its second bid for a group costs order in three class actions against banks over flexible commission schemes after a judge in 2021 rejected what was then the first-ever application for a contingency fee.
Intellectual Property 2021-07-20 8:39 pm
A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.